Xencor, a clinical stage biopharmaceutical firm, is making strides in the discovery and development of monoclonal antibody and cytokine therapeutics aimed at treating cancer and autoimmune diseases. Their product lineup features Sotrovimab, a SARS-CoV-2 virus-targeting medication, as well as Ultomiris and Monjuvi, both aimed at patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and relapsed or refractory diffuse large B-cell lymphoma. Xencor is also working on developing several other promising treatments such as Plamotamab, Vudalimab, XmAb306, XmAb104, XmAb564, AMG 509, XmAb819, Novartis XmAb, XmAb541, and XmAb662, all in varying stages of clinical trials. Additionally, Xencor is focusing on tackling hepatitis B virus infection and influenza A treatment, with VIR-3434 and VIR-2482 in respective phases of clinical trials. The company is also committed to developing AIMab7195, Obexelimab, and Xpro1595, aimed at alleviating symptoms of allergy, autoimmune disease, and Alzheimer's disease, mild cognitive impairment, and depression patients. Xencor, headquartered in Monrovia, California, was founded in 1997 and boasts a license agreement with Caris Life Sciences.
Xencor's ticker is XNCR
The company's shares trade on the NASDAQ stock exchange
They are based in Monrovia, California
There are 51-200 employees working at Xencor
It is xencor.com
Xencor is in the Healthcare sector
Xencor is in the Biotechnology industry
The following five companies are Xencor's industry peers: